KTTAHealthcare · BiotechnologyKTTA Stock Forecast: Pasithea Therapeutics Corp. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Pasithea Therapeutics Corp. hold a median 12-month price target of $3 — +458.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KTTA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Pasithea Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
KTTA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KTTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +458.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 16 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 10 July 2023 | EF Hutton | Reiterates | Buy | $2.00 |
| 1 June 2023 | EF Hutton | Assumes | Buy | $2.00 |
| 3 Apr 2023 | EF Hutton | Maintains | Buy | $2.30 → $2.00 |
| 14 Dec 2021 | EF Hutton | Initiates | Buy | $3.25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KTTA appears on the weeks it earns a place.
KTTA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Pasithea Therapeutics Corp. (KTTA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- 0.4×
- EV / EBITDA
- 1.4×
Cheaper than 78% of US stocks
Cheaper than 88% of US stocks
Cheaper than 57% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −65.5%
- Return on assets
- −36.0%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KTTA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pasithea Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about KTTA stock
What is the KTTA stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Pasithea Therapeutics Corp. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KTTA stock a buy right now?
Of the 1 analysts covering Pasithea Therapeutics Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pasithea Therapeutics Corp. 14 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KTTA?
As at 22 Aug 2026, Pasithea Therapeutics Corp. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
Will KTTA stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +458.2% from the last close, and Ticker Nerd's factor model ranks Pasithea Therapeutics Corp. 14 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KTTA stock forecast for 2030?
No analyst covering Pasithea Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KTTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
How has KTTA stock performed over the past year?
Pasithea Therapeutics Corp. returned -24.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pasithea Therapeutics Corp. do?
Pasithea Therapeutics Corp. is a biotechnology company specializing in the research and development of advanced therapeutics for psychiatry and neurology.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. is a biotechnology company specializing in the research and development of advanced therapeutics for psychiatry and neurology. The company's primary focus lies in discovering innovative solutions for mental health disorders, leveraging cutting-edge science and technology to address unmet medical needs. Pasithea Therapeutics aims to transform the treatment landscape for conditions such as depression, anxiety, and other psychiatric disorders. Driven by a mission to revolutionize mental health care, Pasithea Therapeutics engages in developing proprietary drug candidates and exploring the potential of psychedelic compounds. The company operates within the broader healthcare and biopharmaceutical sectors, contributing to significant advancements in medical research and treatment modalities. Its innovative approach positions it at the forefront of a rapidly evolving industry that seeks to tackle complex mental health challenges. Pasithea Therapeutics is notably committed to expanding therapeutic options, providing an impactful presence in the market as healthcare systems globally strive to enhance mental health outcomes. Through collaboration with research institutions and strategic partnerships, the company plays a vital role in pushing the boundaries of medical science for psychiatry and neurology.
CEO Dr. Tiago Reis Marques M.D., Ph.D. · 5 employees · United States · https://www.pasithea.com